

Ovarian Cancer Survivor Aimee Jungman Joins Clearity Board

Director dedicated to helping other women improve their treatment success

The board of directors of The Clearity Foundation has appointed Aimee Jungman as a director of the non-profit organization dedicated to providing personalized treatment information to women with ovarian cancer. Ms. Jungman is an ovarian cancer survivor who credits members of the Clearity Foundation for saving her life. Clearity's Founder, Dr. Laura Shawver, and Clearity Scientific Advisory Board Chair Dr. Beth Karlan, Director of Gynecologic Oncology at Cedars-Sinai Medical Center, were instrumental in helping Ms. Jungman to understand the unique characteristics of her cancer and personalize her treatment appropriately. She is currently in remission and passionate about supporting The Clearity Foundation in its efforts to increase its capacity to support more ovarian cancer patients nationwide.

"I welcome Aimee to Clearity's board knowing that she will apply the same passion and resourcefulness that she used in advocating for her own treatment to Clearity's mission to help more patients make informed treatment decisions. Aimee's advocacy can help our organization change the way more women with recurrent ovarian cancer choose their best course of treatment," said Clearity Foundation Dr. Laura Shawver.

Ovarian cancer tumors are very different from patient to patient, which means they are likely to respond differently to FDA approved and investigational drugs. By identifying the alterations in each tumor's information pathways, molecular profiling enables the individualization of a patient's treatment by matching those tumor alterations with one or more drugs. The Clearity Foundation has developed a process for generating this personalized diagnostic information using commercially-available molecular profiling technologies and then analyzing the results using its Diane Barton Database. Armed with this analysis, patients are able to work with their medical teams to make better-informed treatment decisions.

"The trial and error approach that has been used for the past 40 years to treat ovarian cancer is not only random and ineffective, but incredibly difficult for a woman going through one chemotherapy after another. I am eager to support The Clearity Foundation's efforts to increase awareness of the opportunity for patients to personalize their treatments guided by the molecular profiles that Clearity offers," said Ms. Jungman, a resident of San Francisco, CA.

Ms. Jungman joins the Clearity board of directors to lend her personal experience as well as professional healthcare expertise to expanding the reach of the organization's education and fundraising initiatives. She currently runs the Healthcare Innovation Strategy Group at frogdesign.com focused on mobile and new media applications in healthcare. She began her career at Accenture as a senior director of Healthcare Strategy followed by a role at pharmaceutical company Pfizer in its Corporate Strategy and Business Development Group. At

Pfizer Ms. Jungman led the Strategic Innovations Team, which incubated new businesses. She completed her MBA at Stanford University where she also completed a fellowship with Stanford's Healthcare Economic Team and former California Governor Pete Wilson. She has over 15 years experience in the development of technology-based medical businesses, many of which have been start-ups such as Scient and RevolutionHealth that went public or were acquired by Fortune 500 companies.

About The Clearity Foundation

The Clearity Foundation is the only 501(c)(3) organization dedicated to helping ovarian cancer patients make more informed treatment decisions with personalized diagnostic information. Every year, more than 14,000 women die of ovarian cancer and approximately 21,000 are newly-diagnosed. When a patient's ovarian cancer returns after standard chemotherapy, a chance for a cure is less than 15%, or less than 3% if she did not respond to initial treatment. Ovarian cancer survivor and scientist Laura Shawver, Ph.D., established The Clearity Foundation to improve treatment options for ovarian cancer patients and change the one-size-fits-all approach. Visit www.clearityfoundation.org to learn how you can help ovarian cancer patients improve their quality of life and live longer.